ReviewJournal of pain research2026
Prevalence and Study-Level Predictors of Chronic Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.
Review in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating adverse effect of neurotoxic chemotherapy agents. Despite its substantial global burden, the prevalence of chronic CIPN (persisting for ≥3 months after completion of chemotherapy) remains uncertain. We aimed to estimate the global prevalence of chronic CIPN and assess variations based on chemotherapy regimen, cancer type, geographic region, and human development index (HDI). Methods: A systematic search of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus was conducted from database inception to May 2025. A random-effects model with Freeman-Tukey transformation was used for meta-analysis. The primary outcome was the global prevalence of chronic CIPN. Subgroup analysis explored prevalence by time since chemotherapy completion, geographic region, chemotherapy regimen, cancer type, and study design. Results: A total of 197 studies from 36 countries (72,794 patients who received chemotherapy, 26,258 with chronic CIPN) were included. The pooled global prevalence of chronic CIPN was 44.50% (95% CI 40.77-48.25). Subgroup analyses revealed significant variation by geographic region, chemotherapy class, and cancer type. Chronic CIPN prevalence was 54.37% (95% CI 48.24-60.45) at 3-12 months post-chemotherapy, 37.12% (95% CI 30.15-44.26) at 12-24 months post-chemotherapy, and 40.36% (95% CI 34.72-46.08) at ≥24 months post-chemotherapy. Conclusion: Chronic CIPN affects a substantial proportion of cancer survivors, with prevalence influenced by time since completion of chemotherapy, geographic region, chemotherapy type, and cancer type. These findings highlight the need for targeted surveillance, prevention, and management, particularly for high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.